Posted on

MINDCURE to Participate in Upcoming Conferences in December 2021

MINDCURE to Participate in Upcoming Conferences in December 2021

VANCOUVER, BC, Dec. 2, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research for psychedelics, today announced that President & Chief Executive Officer, Kelsey Ramsden, will present virtually at H.C. Wainwright’s 2nd Annual Psychedelics Conference, the Psychedelics Now Virtual Conference, the #CanndoraConnect: Women in Psychedelics Conference and the Life Sciences Investor Forum in December.

H.C. Wainwright’s 2nd Annual Psychedelics Conference
DATE: December 6th, 2021
TIME: 7:00a.m. ET
LINK: https://journey.ct.events/view/87e7f660-cb8f-40d3-ad91-8a3cd7a10f75

A webcast of MINDCURE’s presentation will be available on-demand from Monday, December 6th at 7:00a.m. ET. A recording of the presentation will be accessible on MINDCURE’s investor relations website via the above link for 90 days.

Psychedelics Now Virtual Conference
DATE: December 8th, 2021
TIME: 1:00p.m. ET
LINK: https://www.airmeet.com/e/0eaf96e0-47f9-11ec-90a4-bb052aa99b8c

Ms. Ramsden will participate in the ‘Road to Monetization’ webcast panel at the Psychedelics Now Virtual Conference. Please register to view the panel via the link above.

#CanndoraConnect: Women in Psychedelics Conference
DATE: December 8th, 2021
TIME: 3:05p.m. ET
LINK: https://www.eventbrite.ca/e/canndoraconnect-women-in-psychedelics-tickets-162722149329

Ms. Ramsden will also participate in the ‘Exploring Career Opportunities in Psychedelics’ virtual panel at the #CanndoraConnect: Women in Psychedelics Conference. Please register via the link above to view the panel.

Life Sciences Investor Forum
DATE: December 16th, 2021
TIME: 11:30a.m. ET
LINK: https://bit.ly/3cIf2X6

Ms. Ramsden will present virtually at the Life Sciences Investor Forum. An archived webcast will also be made available after the event through the above link.

For more information on the conferences or to schedule a one-on-one meeting with MINDCURE’s management team, please contact KCSA Strategic Communications at mindcureIR@kcsa.com.

The Company also announces it has granted a total of 10,000 stock options to certain employees pursuant to the terms the Company’s long term incentive plan (“Plan”). The stock options are exercisable at a price of $0.29 per share, and are subject to the terms of the Plan.

About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on LinkedIn, Facebook, Twitter, and Instagram.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information
Certain information presented in this news release may constitute “forward-looking information” within the meaning of applicable securities laws regarding MINDCURE and its business. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors could cause actual results to differ materially from the Company’s expectations, including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Mind Cure Health Inc.

For further information:

MINDCURE Investor Relations: investors@mindcure.com, 1-888-593-8995;

Media Inquiries: Annie Graf, Kristin Cwalinski, KCSA Strategic Communications, mindcure@kcsa.com

Posted on

MINDCURE Provides Update on Studies and Clinical Trials

MINDCURE Provides Update on Studies and Clinical Trials

VANCOUVER, BC, Nov. 4, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research for psychedelics, is pleased to provide an operational progress update on the strategic initiatives of its operating segments – MINDCURE Research and MINDCURE Technology.

MINDCURE Research:

Synthetic Ibogaine Production Update
In March 2021, MINDCURE announced the initiation of chemical synthesis routes for the production of fully synthetic ibogaine. In July 2021, the Company applied for patents on two routes to full chemical synthesis and initiated the production of Good Laboratory Practice (“GLP”) ibogaine leading to the production of Good Manufacturing Practice (“GMP”) ibogaine in order to scale and manufacture a global supply of fully synthetic ibogaine. MINDCURE is currently on schedule and expects to have GLP supply available for research partners beginning in Q2 of 2022.

Pre-Clinical Update
MINDCURE confirms that it is preparing to ship ibogaine drug material to its pre-clinical research partner. The material will initially be used for broad cardiac and neurologic screens, with the potential to conduct in-depth behavioral studies. This program has been identified as MSYNTH-001, and the Company expects results from the first studies during the first quarter of 2022.

In addition to advancing the scale of its synthetic ibogaine program, MINDCURE continues to explore options for drug pipeline expansion. Two candidate selection programs are currently underway, known internally as MC-106 and MC-808. The Company will provide further information on these programs in the second quarter of 2022.

Clinical Trial Update
MINDCURE has completed its draft research protocol for the use of MDMA and psychotherapy to treat female sexual hypoactive desire disorder, known as The Desire Project. The Company expects a pre-IND meeting with the FDA to be scheduled in the first quarter of 2022 and for its Phase 2 trial to begin by the third quarter of 2022. Further, site initiation and initial screening are planned for March 2022, with recruitment and enrollment to follow.

“We are proud to report that MINDCURE’s core research programs are progressing rapidly, showcasing our disciplined commitment to advancing MINDCURE’s drug research and commercial production programs. Concurrently, we maintain a focus on identifying opportunities to expand our drug development pipeline,” said Kelsey Ramsden, President & Chief Executive Officer of MINDCURE.

MINDCURE Technology:

Digital Platform iSTRYM Update
The Company released the minimum viable product (“MVP”) of its digital therapeutics (DTx) technology, iSTRYM, into partner clinics across North America in August. MINDCURE is pleased to announce that it has exceeded its previously announced target and timeline of 10 clinics by the end of 2021. The Company has already partnered with 20 ketamine clinics in nine states in the US and three provinces in Canada and plans to expand to the broader mental health market in 2022.

In addition, MINDCURE will begin full commercial deployment to all partner clinics in early 2022, with expansion plans to the UK and Europe by the fourth quarter of 2022.

In addition to its recently announced letter of intent with Awakn Life Sciences Corp. to distribute their Ketamine for Alcohol Use Disorder (“AUD”) protocol in North America via iSTRYM, MINDCURE will expand its selection of existing ketamine protocols with an additional MINDCURE developed protocol in the first quarter of 2022. The Company is continuing on its path toward becoming a leader in the distribution of best-in-class therapy protocols for both partners and providers.

Observational Study Update
MINDCURE is pleased to announce that its Integration Protocol Research Study is complete. As previously announced in March 2021, unconditional ethics approval from Veritas IRB was received for the study. The data has been amassed and findings incorporated into the MVP of iSTRYM. As a next step, the Company’s research partners will submit findings for publication. Understanding integration protocols and practices is an important part of providing best-in-class care specific to psychedelic medicines in practice.

Corporate Update

MINDCURE has further engaged Sandstone Media LLC (“Sandstone”) to provide a broad range of product and brand awareness, marketing and media services, including message development, content creation, social media, advertising, marketing and retargeting, which may include related investor relations services. Sandstone will be paid up to USD$375,000 for the execution and management of the campaign.

Lastly, the Company has granted a total of 30,000 stock options to certain employees pursuant to the terms of the Company’s long term incentive plan (“Plan”). The stock options are exercisable at a price of $0.33 per share and subject to the terms of the Plan.

About MINDCURE
Mind Cure Health (“MINDCURE”) is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally.  Learn more at mindcure.com, and follow us on LinkedIn, Facebook, Twitter, and Instagram.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information
Certain information presented in this news release may constitute “forward-looking information” within the meaning of applicable securities laws regarding MINDCURE and its business. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases.

Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; the Company will develop its products as expected and that they will attain the outcomes anticipated; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that strategic partnerships entered by the Company will create the opportunities and outcomes anticipated; that MINDCURE will advance wellness worldwide; that trading on the OTCQX will attract additional investment and provide additional liquidity for shareholders.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information inherently entails known and unknown risks and uncertainties about the future and actual results and involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: successful clinical studies relating to ibogaine and the Desire Project, successfully synthesizing and manufacturing of ibogaine, the successful development, integration and deployment of iSTRYM, the successful development of appropriate Ketamine protocols, and acquiring adequate protection of any IP developed. Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.

Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

For further information

MINDCURE Investor Relations

investors@mindcure.com

1-888-593-8995

Media Inquiries

Annie Graf / Kristin Cwalinski

KCSA Strategic Communications

mindcure@kcsa.com

Posted on

MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder into Clinics Across United States and Canada through iSTRYM, MINDCURE’s Digital Therapeutics Platform

MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder into Clinics Across United States and Canada through iSTRYM, MINDCURE’s Digital Therapeutics Platform

VANCOUVER, BC, October 28, 2021 – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research for psychedelics, is pleased to announce the signing of a non-binding letter of intent (“LOI”) with Awakn Life Sciences (NEO: AWKN)(OTCQB: AWKNF) (“Awakn”), a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicine to better treat Addiction.

The Company will enter into an agreement with Awakn to be a distributor of its ketamine-assisted psychotherapy for Alcohol Use Disorder (AUD) protocol in the US and Canada. Awakn’s protocol will be distributed through iSTRYM, MINDCURE’s digital therapeutics platform.

MINDCURE released the minimum viable product (MVP) version of iSTRYM into partner clinics across North America in August and will begin full commercial deployment to all partner clinics in Q1 of 2022. The company forecasts 75 partner clinics in Canada and the US deploying iSTRYM upon commercialization. Further deployment anticipates 150 clinics across Canada, the US, the UK, and Europe by Q4 2022.

iSTRYM provides a digital distribution network of science-based protocols developed by MINDCURE’s clinical partners, companies, academic institutions, and other healthcare providers directly to therapists. The Company is already partnering with ketamine-assisted psychotherapy clinics in nine states in the US and two provinces in Canada with plans to expand to the broader mental health market in 2022. The distribution component of iSTRYM unlocks another revenue line for MINDCURE, in addition to clinic and patient level revenues from the platform.

“Awakn’s goal is to fully integrate evidence-backed psychedelic-assisted psychotherapy into mainstream healthcare to better treat addiction. We’re currently building the UK and Europe’s leading chain of medical psychedelic clinics with a focus on treating addiction and other mental health conditions,” said Anthony Tennyson, CEO of Awakn Life Sciences. “We are extremely pleased that we now also have a partnership with MINDCURE to distribute our ketamine-assisted psychotherapy for Alcohol Use Disorder protocol through their iSTRYM platform in the US and Canada.”

Awakn acquired the licensing rights from the University of Exeter for a ketamine-assisted psychotherapy treatment for AUD, which has been validated in a completed Phase II a/b trial. Awakn’s license to use and deliver the ‘Ketamine in the Reduction of Alcoholic Relapse’ (KARE) psychotherapy treatment will be deployed in each of Awakn’s clinics in the UK and Europe and will be led by a consultant psychiatrist. Awakn’s Team includes world leading scientific, research and clinical experts in the treatment addiction, led by Professor David Nutt, who serves as Awakn’s Chief Research Officer and Chair of both the Scientific Advisory Boards (Preclinical and Clinical). The KARE protocol will be distributed by MINDCURE in its digital therapeutic platform across its growing network of clinical partners in the US and Canada.

“Improving mental health is a global challenge and we’re building iSTRYM to be an innovative global solution,” said Kelsey Ramsden, President & CEO, MINDCURE. “This is our first of many overseas partnerships with industry leaders who are developing scientifically rigorous psychedelics protocols and drugs whereby our technology provides a natural distribution partner to support both patients and therapists.”

About Awakn

Awakn Life Sciences (“Awakn”) is a biotechnology company with clinical operations, researching, developing, and delivering psychedelic medicine to better treat Addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat Addiction. Awakn will also deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licencing partnerships globally. Learn more at awaknlifesciences.com.

About MINDCURE

Mind Cure Health (“MINDCURE”) is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on LinkedIn, Facebook, Twitter, and Instagram.

On Behalf of the Board of Directors

Kelsey Ramsden, President & CEO

Phone: 1-888-593-8995

Forward-Looking Information

Certain information presented in this news release may constitute “forward-looking information” within the meaning of applicable securities laws regarding MINDCURE and its business. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases.

Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; the Company will develop its products as expected and that they will attain the outcomes anticipated; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that strategic partnerships entered by the Company will create the opportunities and outcomes anticipated; that MINDCURE will advance wellness worldwide; that trading on the OTCQX will attract additional investment and provide additional liquidity for shareholders

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information inherently entails known and unknown risks and uncertainties about the future and actual results and involves significant risks and

uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: iSTRYM distributing Awakn’s ketamine-assisted psychotherapy for Alcohol Use Disorder protocol in the US and Canada. Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.

Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

For further information:

MINDCURE Investor Relations

investors@mindcure.com

1-888-593-8995

Media Inquiries

Annie Graf / Kristin Cwalinski

KCSA Strategic Communications

mindcure@kcsa.com

Posted on

MINDCURE Announces Participation at Upcoming Events in November 2021

MINDCURE Announces Participation at Upcoming Events in November 2021

VANCOUVER, BC, October 27, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research in psychedelics, today announced that Kelsey Ramsden, President & CEO of MINDCURE, will participate in two upcoming events in November 2021:  

  • Wonderland Miami to be held in-person on November 8-9. MINDCURE will participate as a Silver Sponsor at the largest in-person conference focusing on the psychedelic medicine industry. Ms. Ramsden will participate in a number of panel presentations during the conference.  The event is organized by Microdose Psychedelic Insights (“Microdose”), a portfolio company of Origin Therapeutics. For panel information or to attend, please visit the event website here.
    ‍
  • Mind Medicine Australia (“MMA”) will host an International Summit on Psychedelic Therapies for Mental Illness, to be held virtually from Australia on November 19-20. MINDCURE is a Supporting Partner of MMA, and Ms. Ramsden will participate in a panel presentation called “Creating the Future: What the Psychedelic Industry Will Look Like 5 Years Out”. To attend, please register here.

For more information about the conferences, or to schedule a one-on-one meeting with MINDCURE management, please contact KCSA Strategic Communications at MindCure@kcsa.com.

About Mind Cure Health Inc.

MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on LinkedIn, Facebook, Twitter, and Instagram.

On Behalf of the Board of Directors

Kelsey Ramsden, President & CEO

Phone: 1-888-593-8995 

Forward-Looking Information

Certain information presented in this news release may constitute “forward-looking information” within the meaning of applicable securities laws regarding MINDCURE and its business. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases.

Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; the Company will develop its products as expected and that they will attain the outcomes anticipated; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that strategic partnerships entered by the Company will create the opportunities and outcomes anticipated; that MINDCURE will advance wellness worldwide; and that trading on the OTCQX will attract additional investment and provide additional liquidity for shareholders.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information inherently entails known and unknown risks and uncertainties about the future and actual results and involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.

Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

TheCSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

For further information:

‍MINDCURE Investor Relations

investors@mindcure.com

1-888-593-8995

‍Media Inquiries

Annie Graf / KristinCwalinski

KCSA StrategicCommunications

mindcure@kcsa.com

Posted on

MINDCURE Announces Financial Results for the First Quarter of Fiscal 2022

MINDCURE Announces Financial Results for the First Quarter of Fiscal 2022

VANCOUVER, BC, Oct. 26, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research for psychedelics, today announced its financial results for the three months ended August 31, 2021.  All amounts are stated in Canadian dollars unless otherwise indicated.  

Q1 Fiscal 2022 Business Highlights

  • Released the minimum viable product version of iSTRYM, the Company’s digital therapeutics (DTx) platform, into partner clinics across North America;
  • Completed full chemical synthesis of ibogaine, launched the second stage of manufacturing, and filed two provisional patent applications;
  • Developed proprietary ketamine-enhanced psychotherapy protocols for treatment of pain and depression;
  • Completed a strategic equity investment in Awakn Life Sciences Inc.;
  • Signed exclusive digital clinical data licensing agreement with ATMA Journey Centers; and
  • Subsequent to quarter end, introduced the “Desire Project”, a clinical research program focused on the treatment of female hypoactive sexual desire disorder with MDMA-assisted psychotherapy.

“Q1 was a significant quarter for MINDCURE, as we achieved several key milestones including the launch of the minimum viable product of iSTRYM, our digital therapeutics platform,” stated Kelsey Ramsden, President & CEO of MINDCURE.  “We closed the quarter with a strong cash position and have a solid pipeline of catalysts over the next few months. I look forward to sharing more updates as we continue to prepare iSTRYM for commercial deployment, progress in the manufacturing of ibogaine, and advance our Desire Project.”

Q1 Fiscal 2022 Financial Highlights

  • Cash and cash equivalents totalled $15.6 million as at August 31, 2021;
  • Net loss for the three months ended August 31, 2021 was $2.8 million, comprised of non-cash operating expenses of $0.3 million, an inventory write down of $0.2 million; an unrealized investment loss of $0.1 million, and cash operating expenses of $2.2 million.

A copy of the Company’s financial statements for the three months ended August 31, 2021, and the related management’s discussion and analysis are available under the Company’s profile on SEDAR at www.sedar.com.

In other news, the Company announces it has granted a total of 70,000 stock options to certain employees pursuant to the terms the Company’s long term incentive plan (“Plan”). The stock options are exercisable at prices between $0.295 per share and $0.325 per share and are subject to the terms of the Plan. The Company further announces it has issued 108,224 common shares to a consultant at agreed-upon prices between $0.31 per share and $0.60 per share.

About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.

On Behalf of the Board of Directors

Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information
Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that iSTRYM will be developed, optimized and operate as contemplated within the psychedelics industry; that the Company will be effective in obtaining the patents applied for synthesizing ibogaine, or synthesizing ibogaine, or developing synthesized ibogaine for research, medical or commercial use; that MINDCURE will advance wellness worldwide; that iSTRYM will be brought to commercial deployment in the near term or otherwise or that it will reduce symptoms, improve quality of life, or support transformation and healing, or that the deployment may not occur at the scale or within the time frame contemplated.

Although MINDCURE has attempted to identify important factors that could cause actual results,  performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.

Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

For further information: MINDCURE Investor Relations, investors@mindcure.com, 1-888-593-8995; Media Inquiries, Annie Graf / Kristin Cwalinski, KCSA Strategic Communications, mindcure@kcsa.com

Posted on

Hey ladies, get those butterflies back with MDMA: issue 19

Here’s what’s in store for you in today’s issue:

🍄 Preventing depression legally

🍄 Inhaling shrooms?

🍄 The cure for low sex drive

🍄 Why your employer should let you do drugs

🍄 And more.

You’ll want to stay till the end to learn how someone found enlightenment on a trippy hike.

(Did a good friend forward this to you? If so be sure to subscribe here)

Be sure to check out this week’s Daily Mushroom podcast:
Psychedelic medicines could hold a promise never seen before in mental healthcare

In this episode we have Dave Philips, a registered clinical counselor who has integrated psychedelic therapy into his practice. Dave talks about how he is training the next generation of psychedelic counselors and how he started in this extraordinary field.

Therapeutic banner

How to prevent depression legally

Even non-psychedelic mushrooms could lower your risk of depression!

Researchers from the Penn State College of Medicine collected data from 24,000 Americans and discovered that those who ate mushrooms had a lower chance of being depressed.

Mushrooms are the highest dietary source of ergothioneine, an antioxidant that may prevent mental illnesses by reducing oxidative stress protecting against cell damage. 

While the study didn’t factor in different types of mushrooms, white buttons are believed to ease anxiety and Lion’s Mane can promote neurogenesis which may prevent mental disorders.

Therapy is hard…but drugs help!

Patients with treatment-resistant depression (TRD) often struggle with concentration, mood and motivation, which can make therapy challenging or unsuccessful. Can psilocybin’s immediate mood-boosting effect enhance engagement in therapy?
 
Monash University is seeking funding from the Australian government for a proposed 2b clinical trial that would reveal the answer.
 
The study would use proprietary biomarker technology developed by MYND Diagnostics Inc., a subsidiary of MYND Life Sciences (MYND), to monitor blood indicators of the subjects’ response, progress, and any relapsing to the psilocybin treatments. If successful, a multi-site phase 3 adaptive trial would follow within a year of completion to get psilocybin-assisted therapy approved by the Therapeutic Goods Association.

Never leave home without your inhaler 😉

Cybin Inc. (CYBN) developed a new device that delivers psychedelic medicine through inhalation.

Inhaling psychedelics could be superior to oral administration, as it could result in optimized session timing, lower doses, and greater control for healthcare providers.

The company filed an international patent application for the method and the device, which has potential to gain coverage in 153 countries.

inspirational banner

Is MDMA the Viagra for women?

A Vancouver company called LOVE Pharma (LUV) wants to promote mental and sexual wellness with its growing product line. 

The company recently launched two products (a CBD oral strip and a clitoral stimulation gel) and has exclusive rights to a total of seven novel therapeutic products. It’s currently developing a biosynthetic psilocybin strip using the IP from the CBD strip.

On Tuesday, the company was listed on  the Frankfurt Stock Exchange under the symbol “G1Q0”.

In other sexual wellness news, Mind Cure Health (MCUR) recently launched a research program to treat female hypoactive sexual desire disorder (HSDD), a disorder involving low sex drive and emotional distress, with MDMA-assisted therapy.

How shrooms are saving the butterflies!

An eye-opening psychedelic journey inspired this former Navy SEAL save the butterflies while helping veterans cope with trauma.

Mark Matzeldelaflor founded a nonprofit called Guardian Grange after a magic mushroom trip showed him the healing power of nature.

“I just reconnected to nature and my past, where I was like a kid in the woods. And I realized there’s so much healing in being outside in nature, getting your hands in the dirt and doing good work,” he said.

The organization provides a safety net for veterans where they can learn about conservation, sustainability and regenerative agriculture while transitioning back to civilian life. Its first major initiatives is to build a preserve for Western monarch butterflies, which have had a 99.9% population decline in California.

Why your employer should let you do drugs

Psych’s third annual report on psychedelic medicine revealed some interesting findings.

According to a survey of 440 healthcare professionals working in various fields, two thirds said they were excited about psychedelics as medicines. Of those who’ve personally tried the drugs for therapeutic or spiritual purposes, 83% were in favour of psychedelic medicine.

Consumers also showed a positive view of psychedelics, with about two thirds supporting medical legalization and 38% noting that someone they know would benefit from psychedelic therapy. When asked which psychedelic they would want to try in therapy, psilocybin and salvia were the most popular choices.

The report also showed that psychedelic therapy could save employers US$64 billion in Europe and US$270 billion in America due to fewer sick days and increased productivity.

business banner

New advisor supports expansion into psychedelic treatments

Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) is accelerating its expansion into psychedelic and mental health treatments with a new addition to its team.

Yesterday, Blackhawk appointed Dr. Lahiru Russell, the founder and chief scientist of Digital Health Technologies, as the company’s medical advisor. Using her 10+ years of experience in clinical trials and psycho-oncology research, Dr. Russel is developing a mindfulness-based intervention platform that will help patients regulate their emotions and thoughts to reduce negative mental health conditions.

Blackhawk’s subsidiary, MindBio Therapeutics, will be able to utilize Dr. Russel’s IP in its microdosing research through a commercialization agreement with Digital Mind Technology, which was established last month.

MindBio will also utilize Google Cloud’s “Health Care Solutions” to recruit, enroll, and engage with patients in its internal clinical trials and to accelerate drug development.

A new subsidiary to tackle depression

atai Life Sciences (ATAI) and Chymia LLC launched a new company to offer individualized care for patients with treatment-resistant depression (TRD).

The company, PsyProtix, takes a precision psychiatry approach – an emerging method that treats illnesses based on each patient’s genetic, metabolic, environmental, and lifestyle variability.

The platform should allow patients to be diagnosed and treated faster and more effectively than when following protocols designed for the majority.

Measuring brain penetration?

Mindset Pharma (MSET) is rapidly expanding its pipeline thanks to advancements made by its Co-operative Psychedelics Evaluation (COPE) program, which aims to develop preclinical benchmark data for psychedelic medicines.

Researchers established standard pharmacokinetic, brain penetration, and drug discrimination data and protocols for psilocybin, LSD, and 5-MeO-DMT. The company also developed procedures to determine concentrations of the drugs in plasma, brain, and cerebral spinal fluid.

These finding, which were gathered in collaboration with InterVivo Solutions, will help drug developers understand how compounds interact with the body. Mindset will commercialize the data by making it available to other InterVivo clients.

legal banner

Another win for California

With a unanimous vote, Arata became the third city in California to decriminalize psychedelics!

The possession, cultivation and distributions of entheogens including psilocybin and ayahuasca will become the city’s lowest law enforcement priority, but commercial sale will remain illegal.

The measure represents “a pivotal point in history by reclaiming our sovereign right to explore our consciousness, and to choose the path of healing that we see best fit for ourselves,” according to an organizer of the activist group Decriminalize Nature Humboldt.

We told you decriminalization isn’t risky!

It’s been over two years since Denver decriminalized mushrooms, and a recent report shows that people are using psilocybin responsibly.

The Denver Psilocybin Mushroom Policy Review Panel, which is comprised of local officials, law enforcement, and scientific experts, unanimously agreed that there have been no significant public health or safety risks as a result of the reform.

The panel proposed that the city’s next steps should be to train first responders to respond to psychedelic crises, create public service announcements on psychedelic safety, and deprioritize the sharing, gifting, and communal use of psilocybin, among other recommendations.

Support for first responders

The push for psilocybin research is gaining traction in Pennsylvania.

Twenty one lawmakers from both parties sponsored a bill called the Public Heath Benefits of Psilocybin Act, which would set up a research framework to optimize psilocybin’s public health benefits. Studies focused on veterans, retired first responders, and their families would be prioritized.

“A growing body of research provides a reason for hope that psilocybin, administered in a controlled setting, will be the most effective tool at our disposal to combat the suicide, opioid and overall mental health crisis burdening the Commonwealth,” the group wrote to colleagues.

Industry Quick Hits

Oct 8 – Numinus (NUMI) Upgrades Psychedelics Lab to Increase Research Service Capabilities Read more…

Oct 11 – Cannabis Global (CBGL) Selects Oakland, CA for New Mushroom-based Psychedelics Infusion Research Initiative Read more…

Oct 13 – Novamind (NM) Granted DEA Licenses for Psilocybin Research Read more…

Oct 13 – MindMed (MNMD) Joins Clinical Trials Transformation Initiative Read more…

Oct 13 – Psyence Group (PSYG) Announces Commencement Of Trading On OTCQB And DTC Eligibility Of Common Shares In The United States Under The Ticker “PSYGF” Read more…

Oct 14 – Delic Corp’s (DELC) Ketamine Wellness Centers Partners with Veterans Affairs Community Care Network to Provide Free Ketamine Treatments to Veterans Read more… 

Video of the Week

Thomas Hartle Advocates for Medical Psilocybin Regulations - TheraPsil

🌲+🌧️+🍄=✨

This Reddit user found enlightenment after taking a mega dose of Golden Teachers in the forest.

“I like to combine mushrooms and hiking. The forecast called for rain on this day. Generally not the best hiking weather, unless there’s shrooms involved.

Once they kicked in I went into this deep meditation. I started to think about current events in my life, but as if I was looking at them from a completely different set of eyes. I was so deep in meditation that I didn’t realize it had started raining. I slowly came to the realization that I was soaking wet. Normally that might have made me feel uncomfortable. I stood up and felt ready for anything this world could throw at me.

I looked around and the visualizations were quite extreme. All of the landscape around me was shifting and moving. It looked like the whole earth was breathing. The patterns in the bark of the trees were moving. I found this big rock under a tree and laid flat on my back. At this point it was raining pretty hard. I could feel every raindrop hitting my face. I could see the droplets falling through the sky as if it was slow motion. The raindrops dripping from the surrounding leaves and branches seemed to be frozen in time. My concept of time itself was totally lost. I felt like I had been laying under that tree for days.

It started to get dark and was still raining. I could hear thunder in the distance. The forest looked so enchanting and I felt like I was in the most magical place. I left the forest and watched the lightning in the distance until the trip wore off. I wasn’t even slightly bothered by the fact that I was totally drenched from head to toe.“

Playlist of the Week

Psychedelic rock
Posted on

Is MDMA the Viagra for women?

LOVE PHARMA INC., ANNOUNCES LISTING ON FRANKFURT STOCK EXCHANGE

A Vancouver company called LOVE Pharma (LUV) wants to promote mental and sexual wellness with its growing product line.

The company recently launched two products (a CBD oral strip and a clitoral stimulation gel) and has exclusive rights to a total of seven novel therapeutic products. It’s currently developing a biosynthetic psilocybin strip using the IP from the CBD strip.

On Tuesday, the company was listed on  the Frankfurt Stock Exchange under the symbol “G1Q0”.

In other sexual wellness news, Mindcure (MCUR) recently launched a research program to treat female hypoactive sexual desire disorder (HSDD), a disorder involving low sex drive and emotional distress, with MDMA-assisted therapy.

PDF of article 1

PDF of article 2

Posted on

MINDCURE to Webcast Live at the KCSA Psychedelics Virtual Investor Conference on October 13, 2021

MINDCURE to Webcast Live at the KCSA Psychedelics Virtual Investor Conference on October 13, 2021

MINDCURE invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com

VANCOUVER, BC, Oct. 7, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research for psychedelics, today announced that President & Chief Executive Officer, Kelsey Ramsden will present virtually at the KCSA Psychedelics Investor Conference on Wednesday, October 13, 2021, which will be held at VirtualInvestorConferences.com.

DATE: October 13, 2021
TIME: 12:00pm ET
LINK: https://bit.ly/3kObcQO

This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.

Learn more about the event at www.virtualinvestorconferences.com.

About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on LinkedIn, Facebook, Twitter, and Instagram.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information
Certain information presented in this news release may constitute “forward-looking information” within the meaning of applicable securities laws regarding MINDCURE and its business. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases.

Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; the Company will develop its products as expected and that they will attain the outcomes anticipated; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that strategic partnerships entered by the Company will create the opportunities and outcomes anticipated; that MINDCURE will advance wellness worldwide; that trading on the OTCQX will attract additional investment and provide additional liquidity for shareholders.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information inherently entails known and unknown risks and uncertainties about the future and actual results and involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: trading on the OTCQX enhancing the visibility of MINDCURE and its strategic growth objectives to a larger subset of the investment community, while materially increasing its share liquidity and capturing additional capital markets attention to facilitate growth initiatives and deliver long-term shareholder value. Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.

Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

For further information: MINDCURE Investor Relations, investors@mindcure.com, 1-888-593-8995; Media Inquiries, Annie Graf / Kristin Cwalinski, KCSA Strategic Communications, mindcure@kcsa.com

Posted on

Elon takes shrooms to the moon!: issue 17

Here’s what’s in store for you in today’s issue:

🍄 Struggling with negative self image

🍄 Pneumonia drug + shrooms repair the brain?

🍄 Build your brain without getting high

🍄 Is Elon going to take shrooms to the moon?

🍄 And more.

You’ll want to stay till the end to learn how someone became a cartoon on magic truffles!

(Did a good friend forward this to you? If so be sure to subscribe here)

Be sure to check out last week’s Daily Mushroom podcast!
Psilocybin, is it the next cannabis wave?

In this episode we have Lenny Kerman, a strategic financial consultant who works with various psilocybin and cannabis companies. He talks about how he’s invested in the space and has some valuable information for those looking to invest as well.

Therapeutic banner

Struggling with a negative self image?

A recent study suggests that repeated psychedelic drug use may be effective in reducing PTSD symptoms and internalized shame in people who endured maltreatment during childhood.

The researchers surveyed adults with severe physical, emotional, or sexual trauma and found that those who took psychedelics for therapeutic purposes (in non-clinical settings) were less likely to have a negative self-concept or disturbances in relationships.

Participants who used psychedelics with therapeutic intent 5 times showed the lowest levels of internalized shame and complex trauma.

Enhancing psilocybin…with a pneumonia drug?

A drug that loosens mucus in the lungs could also help treat concussions!?

Lobe Sciences (LOBE) discovered that psilocybin might work better when paired with N-Acetylcysteine (NAC), a drug used to treat Tylenol overdose and respiratory conditions like pneumonia, bronchitis, and asthma.

In rodent models of mild traumatic brain injury (TBI) and PTSD, the combination of psilocybin and NAC performed significantly better than psilocybin, NAC, or a placebo alone.

The company is working on finding a supplier of high purity cGMP psilocybin to continue research and expand on these findings.

Reducing fish seizures

This Vancouver company is making advancements across its drug pipeline.

Dravet Syndrome, a disorder that causes epilepsy from a young age, is the target of a new study by Bright Minds (DRUG). In preclinical studies on zebrafish, DRUG was effective in reducing seizure duration and frequency and is now on track to be tested in human trials early next year.

In rat models, DRUG showed efficacy in treating opioid use disorder and binge eating disorder with rats demonstrating a 50% reduction in binge eating episodes.

The company also has a mixed compound that is in preclinical development for cluster headaches, chemotherapy-induced peripheral neuropathy, and other pain disorders.

inspirational banner

Tripping in Times Square

This week, the first-ever psychedelic billboard campaign debuted in Times Square to spark a conversation about the healing power of plant medicines and disrupt profit-driven ads.

The #CelebratePlantMedicine campaign encourages viewers to share their personal experiences with plant medicines to destigmatize the use of psychedelics. It also aims to amplify the importance of set and setting, integration, and respecting Indigenous wisdom.

The campaign is run by DoubleBling Magazine, Musings Magazine, Rainbo Mushrooms, and Honeysuckle Magazine, which ran Time Square’s first cannabis billboard.

Go share your story with the hashtag to join the movement!

3 women + microdosing = )

Chelsea says that microdosing allows her to “stay fully present” and is the only tool that helps her focus her busy mind, but the biggest shift was in her anxiety. “For over fifteen years, I had severe anxiety, but through microdosing, I could sit with and deliberate my fears. I now rarely suffer with it, and if I do, it’s fleeting,” she shares.

One woman, Amber, was so depressed that everything felt dull and uninteresting, until she started microdosing. “When I microdosed for the first time I found myself noticing the beauty of the things around me again,” she says. She explains that microdosing is “akin to a child-like wonder” and makes her feel “more positive, open-minded and creative but still completely functional and sober”.

Bea finds that microdosing three times per week acts as a natural mood booster and study aid, brings her mental clarity, and helps her organize her life. She says she’s now able to be her true, stable self and is no longer the “people-pleasing, anxious version” of herself.

Is Elon going to take shrooms to the moon? 

Elon Musk has been known to have a major influence on the stock market, with his Tweets causing Bitcoin and Dogecoin to skyrocket almost instantaneously. His latest interview could take shroom stocks to the moon 😉

In an interview with Ronan Levy, co-founder of Field Trip Health (FTRP), Musk was asked what role he thinks psychedelics have in “addressing some of the more destructive tendencies of humanity.”

Elon replied, “I think, generally, people should be open to psychedelics. A lot of people making laws are kind of from a different era, so I think, as the new generation gets into political power, I think we will see greater receptivity to the benefits of psychedelics.”

business banner

Build a better brain without getting high

“We are not a one- or two-asset company. We’ve got a large pipeline coming out,” warns David E. Olson, founder of Delix Therapeutics.

The Boston-based startup just raised $70 million in series A financing to develop psychedelic-inspired compounds that are safe enough to take at home.

The company has already synthesized about 1,000 compounds across 8+ classes of psychedelics, with the goal of creating compounds that form synapses between brain cells without inducing hallucinations.

The researchers have found a couple of promising contenders, which are on track to be studied in Phase 1 clinical trials by the end of this year.

Are stoners getting bored with cannabis?

These two companies are joining forces to become a leader in commercialized psilocybin extracts.

Pure Extracts (PULL), a cannabis, hemp, and mushroom extraction company, signed a Joint Venture agreement with Psyence Group (PSYG) to form “Pure Psyence”.

The agreement leverages Psyence Group’s licensed cultivation facility and standardized psilocybin mushroom supply to create high-purity, naturally-derived mushroom extracts. Yesterday, Psyence Group completed its first official validated harvest, bringing it one step closer to receiving a British Standards Institute (BSI) certification.

The combined expertise will make standardized psilocybin more accessible to Canadian research institutions and will allow Pure Psyence to conduct human clinical trials using the extracts.

legal banner

Healing the Armed Forces

The US government is funding psychedelic research to get military members the relief they deserve!

A new measure, filed by Rep. Dan Crenshaw of Texas, would allow the Secretary of Defense to award research grants to study psychedelic therapy as a PTSD treatment for active military members.

The measure would allow any State or Federal agency, academic institution, or nonprofit to study the therapeutic effects of psilocybin, ibogaine, MDMA, or 5-MeO-DMT. If passed, funds could be used for Phase 2 clinical studies involving members of the Armed Forces or to train practitioners to offer the treatment.

Another city decriminalizes psychedelics

Well, kind of…

In a 5-2 vote, Grand Rapids, Michigan approved a psychedelics decriminalization resolution, yet activists feel the measure falls short.

The resolution calls for law enforcement deprioritization for use and possession of psilocybin, peyote, ayahuasca, and ibogaine, but it doesn’t address the cultivation, purchase, transportation or distribution of the entheogens, unlike the measure passed in Ann Arbor.

On the bright side, the measure notes that the Mayor and City Commission will support efforts to decriminalize the entheogenic plants and fungi on a local, state, and federal level.

Psychedelic research coming to Florida

“The science regarding psilocybin is real, cannot be ignored, and soon will be a universally-accepted form of treatment in the U.S.,” said Rep. Michael Grieco (D) of Florida.

That’s why he and Senate Minority Leader Lauren Book (D) filed bills that would require the state to study the medical potential of psilocybin and MDMA.

The bills were modeled on the measure enacted in Texas earlier this year to study psychedelic therapy for veterans with PTSD, but with an even broader scope. If enacted, the Department of Health would be directed to research other conditions like depression, anxiety, bipolar disorder, chronic pain and migraines.

Industry Quick Hits

Sept 27 – Clearmind Medicine (CMND) To Fund Second R&D Partnership With Hebrew University’s Technology Transfer Company Read more…

Sept 27 – Nikean Foundation announces $5 million gift to create a Psychedelic Psychotherapy Research Centre at Toronto’s University Health Network (UHN) Read more…

Sept 27 – Delic (DELC) Closes C$7.0 Million Private Placement With U.S. Institutional Investor to Fuel Growth of Largest National Presence Read more…

Sept 28 – NeonMind (NEON) Advances Strategy For Specialty Clinic Launch Read more…

Sept 28 – PharmaTher (PHRM) Announces Closing of CAD$10 Million Private Placement with Institutional Investors Read more…

Sept 29 – MYND Life Sciences Inc. (MYND) Announces RSU Grant Read more…

Sept 29 – Blackhawk Growth’s (BLR) Mindbio Therapeutics Signs Collaboration Agreement With Digital Mind Technology Technology Read more… 

Sept 30 – MINDCURE Announces Commencement of Trading on the OTCQX Best Market Under Symbol ‘MCURF’ Read more…

Sept 30 – Novamind (NM) Opens 6th Integrative Psychiatry Clinic, Adds 3rd Clinical Research Site Read more… 

Video of the Week

LIFE BEYOND: Chapter 1

Becoming an extremely pleasing ball of flesh

This Reddit user had a memorable first trip on magic truffles.

“We cycled to an extremely secluded hill with trees covering it from all sides and where no one ever goes. It’s our secret chill spot mostly used for smoking weed. We sat down in pure awe of the spot and nature. Generating sentences and word combinations was EXTREMELY HARD, because every time we wanted to get a thought out, when we started explaining it, our brains had already moved on to the next thought. It was a rapid fire of thoughts and ideas and we laid down looking at the sky and the trees in silence just thinking about the universe and different topics.

Everything had patterns and colors were extremely bright and vibrant. Everything was breathing and flowing and when I looked at my phone, I couldn’t decipher words as all the letters on my keyboard and screen kept moving and switching places. I didn’t see words, but rather letter combinations. Looking at the camera, my face was constantly moving, shrinking and getting bigger. My eyes looked big and cartoony. It looked like I was living in a cartoon as everything looked like a drawing and too symmetrical to be real. At one point I pressed my head against my knee and felt like my body was merging into a ball of flesh, but it felt extremely pleasing. Everything was positive, loving and peaceful. I was at peace with myself and the universe. Orange juice tasted amazing. Me and my friend didn’t have much interaction as we were both fully engulfed in the trip. He told me afterwards that he had many similar effects to me.

At the end of the peak, I noticed my friend shedding tears and put my hand on his shoulder and asked him if everything was ok. He said he wasn’t sad, but they were rather tears of joy and acceptance. Seems like he was having an even more intense experience than me, but he said his trip was extremely good just like mine and no signs of a bad trip or negative thoughts.”

Playlist of the Week

Psychedlic and Chill
mushroom balloon
Posted on

MINDCURE Announces Commencement of Trading on the OTCQX Best Market

MINDCURE Announces Commencement of Trading on the OTCQX Best Market

VANCOUVER, BC, Sept. 30, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research for psychedelics, announced today that it has graduated from OTCQB Venture Market to now trade on the OTCQX Best Market (“OTCQX“), the highest tier of OTC Markets Group.

MINDCURE begins trading today on OTCQX under the symbol “MCURF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

“Receiving approval to trade on the OTCQX is an important milestone for MINDCURE, validating the outstanding efforts of our entire team to build a leading psychedelics company and to drive value for patients, therapists, clinics and shareholders,” said Kelsey Ramsden, President & Chief Executive Officer of MINDCURE. “Trading on the OTCQX Market enhances the visibility of MINDCURE and our strategic growth objectives to a larger subset of the investment community, while increasing our share liquidity and capturing additional capital markets attention to facilitate our growth initiatives and deliver long-term shareholder value.”  

Michael Wolfe, Chief Financial Officer of MINDCURE stated: “The Company is focused on innovating mental health treatments that combine technology, data, and research to empower individuals in their mental wellness journey. Trading on the OTCQX will provide MINDCURE with broader access to capital, a wider investor base and ultimately drive value for our shareholders.”

The OTCQX Market is designed for established, investor-focused U.S. and international companies. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. Graduating to the OTCQX Market from the OTCQB Market marks an important milestone for companies, enabling them to demonstrate their qualifications and build visibility among U.S. investors.

About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on LinkedIn, Facebook, Twitter, and Instagram.

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market and the Pink® Open Market for 11,000 U.S. and global securities.  Through OTC Link® ATS and OTC Link ECN, OTC Markets connects a diverse network of broker-dealers that provide liquidity and execution services. OTC Markets enables investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors. To learn more about OTC Markets Group Inc., visit www.otcmarkets.com.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information
Certain information presented in this news release may constitute “forward-looking information” within the meaning of applicable securities laws regarding MINDCURE and its business. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: the trading of the Company on the OTCQX and its benefits to the Company.

Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; the Company will develop its products as expected and that they will attain the outcomes anticipated; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that strategic partnerships entered by the Company will create the opportunities and outcomes anticipated; that MINDCURE will advance wellness worldwide; that trading on the OTCQX will attract additional investment and provide additional liquidity for shareholders.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information inherently entails known and unknown risks and uncertainties about the future and actual results and involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: trading on the OTCQX enhancing the visibility of MINDCURE and its strategic growth objectives to a larger subset of the investment community, while materially increasing its share liquidity and capturing additional capital markets attention to facilitate growth initiatives and deliver long-term shareholder value. Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.

Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

For further information: MINDCURE Investor Relations- investors@mindcure.com, 1-888-593-8995; Media Inquiries- Annie Graf / Kristin Cwalinski, KCSA Strategic Communications, mindcure@kcsa.com